Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops, and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular, and other diseases with high unmet medical need. For more information, please visit www.daiichisankyo.com.

contact: Christophe.Fremin@daiichi-sankyo.eu

Special Issue “Current Challenges in Geriatric Oncology”

Guest Editors: Prof. Dr. Kwok-Leung Cheung and Dr. Holly M. Holmes

Deadline for manuscript submissions: 15 March 2024